The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,317 | -15,716 | -14,259 | -36,514 |
| Depreciation and amortization | 15 | 17 | 19 | 240 |
| Share-based compensation | 5,073 | 1,825 | 1,238 | 5,305 |
| Amortization of premium and discount on marketable securities | -206 | -1,196 | -375 | -102 |
| Rou asset amortization | 353 | 353 | 352 | 491 |
| Prepaid expenses and other current assets | 87 | -312 | -4,021 | -783 |
| Accounts payable | -679 | -1,510 | 500 | 346 |
| Accrued expenses | -3,383 | 2,699 | -2,308 | 4,705 |
| Operating lease liability | -38 | -38 | -37 | -294 |
| Net cash used in operating activities | -17,269 | -13,254 | -10,849 | -25,040 |
| Purchase of property and equipment | 82 | 0 | 7 | 18 |
| Purchases of marketable securities | 44,815 | 27,475 | 109,077 | 58,005 |
| Proceeds from sale or maturities of marketable securities | 83,326 | 24,097 | 13,928 | 63,251 |
| Net cash provided by investing activities | 38,429 | -3,378 | -95,156 | 5,228 |
| Proceeds from issuance of common stock and warrants | - | 0 | 137,999 | 0 |
| Issuance costs from issuance of common stock | - | 0 | 8,638 | 0 |
| Proceeds from exercise of common stock | 3,854 | 1,275 | - | - |
| Taxes paid related to net shares settlement of rsus | 489 | 212 | 0 | 815 |
| Net cash provided by (used in) financing activities | 3,365 | 1,063 | 129,361 | -815 |
| Net change in cash, cash equivalents and restricted cash | 24,525 | -15,569 | 23,356 | -20,627 |
| Cash, cash equivalents and restricted cash at beginning of period | 31,211 | 46,780 | 44,051 | - |
| Cash, cash equivalents and restricted cash at end of period | 55,736 | 31,211 | 46,780 | - |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)